<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36774419</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Vaccination status and long COVID symptoms in patients discharged from hospital.</ArticleTitle><Pagination><StartPage>2481</StartPage><MedlinePgn>2481</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2481</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-28839-y</ELocationID><Abstract><AbstractText>Effective vaccination against coronavirus mitigates the risk of hospitalisation and mortality; however, it is unclear whether vaccination status influences long COVID symptoms in patients who require hospitalisation. The available evidence is limited to outpatients with mild disease. Here, we evaluated 412 patients (age: 60&#x2009;&#xb1;&#x2009;16&#xa0;years, 65% males) consecutively admitted to two Hospitals in Brazil due to confirmed coronavirus disease 2019 (COVID-19). Compared with patients with complete vaccination (n&#x2009;=&#x2009;185) before infection or hospitalisation, those with no or incomplete vaccination (n&#x2009;=&#x2009;227) were younger and had a lower frequency of several comorbidities. Data during hospitalisation revealed that the no or incomplete vaccination group required more admissions to the intensive care unit (ICU), used more corticosteroids, and had higher rates of pulmonary embolism or deep venous thrombosis than the complete vaccination group. Ninety days after hospital discharge, patients with no or incomplete vaccination presented a higher frequency of symptoms (&#x2265;&#x2009;1) than patients with complete vaccination (40 vs. 27%; p&#x2009;=&#x2009;0.013). After adjusting for confounders, no or incomplete vaccination (odds ratio [OR] 1.819; 95% confidence interval [CI] 1.175-2.815), female sex (OR 2.435; 95% CI 1.575-3.764) and ICU admission during hospitalisation (OR 1.697; 95% CI 1.062-2.712) were independently associated with&#x2009;&#x2265;&#x2009;1 symptom 90&#xa0;days after hospital discharge. In conclusion, even in patients with severe COVID-19, vaccination mitigates the probability of long COVID symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Teresa Cristina D C</ForeName><Initials>TCDC</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil. teresa.cdcnascimento@hsl.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>do Valle Costa</LastName><ForeName>Livia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Amanda Danieletto</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledo</LastName><ForeName>Carla B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Valeria Paes Lima</ForeName><Initials>VPL</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, Bras&#xed;lia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>Luiz Francisco</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junior</LastName><ForeName>Jos&#xe9; Mauro Vieira</ForeName><Initials>JMV</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saretta</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil-Filho</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drager</LastName><ForeName>Luciano F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Hospital S&#xed;rio Liban&#xea;s, S&#xe3;o Paulo, Brazil. luciano.drager@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. luciano.drager@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36774419</ArticleId><ArticleId IdType="pmc">PMC9922040</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-28839-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-28839-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, et al. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K, et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron. Respir. Dis. 2021;18:14799731211002240. doi: 10.1177/14799731211002240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14799731211002240</ArticleId><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, COVICARE Team et al. COVID-19 symptoms: Longitudinal evolution and persistence in outpatient settings. Ann. Intern. Med. 2021;174:723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N. Engl. J. Med. 2021;385:2421&#x2013;2430. doi: 10.1056/NEJMoa2115926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115926</ArticleId><ArticleId IdType="pmc">PMC8728796</ArticleId><ArticleId IdType="pubmed">34879188</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 2021;385:875&#x2013;884. doi: 10.1056/NEJMoa2107715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107715</ArticleId><ArticleId IdType="pmc">PMC8279092</ArticleId><ArticleId IdType="pubmed">34233097</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav. Immunol. 2022;103:154&#x2013;162. doi: 10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Pijnenburg L, Chatelus E, et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: Results from the nationwide VAXILONG study. Vaccines. 2021;10:46. doi: 10.3390/vaccines10010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010046</ArticleId><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, et al. Trajectory of long COVID symptoms after COVID-19 vaccination: Community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO definition. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.</Citation></Reference><Reference><Citation>Notarte, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey, et al. Change in symptoms and immune response in people with post-acute sequelae of SARS-CoV-2 infection (PASC) after SARS-CoV-2 vaccination. medRxiv. 2021 doi: 10.1101/2021.07.21.21260391v2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Visco V, et al. Post-COVID-19 syndrome: Involvement and interactions between respiratory, cardiovascular and nervous systems. J. Clin. Med. 2022;11:524. doi: 10.3390/jcm11030524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030524</ArticleId><ArticleId IdType="pmc">PMC8836767</ArticleId><ArticleId IdType="pubmed">35159974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, et al. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet. 2021;398:2093&#x2013;2100. doi: 10.1016/S0140-6736(21)02249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02249-2</ArticleId><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen O, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N. Engl. J. Med. 2022;386:1603&#x2013;1614. doi: 10.1056/NEJMoa2201688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201688</ArticleId><ArticleId IdType="pmc">PMC9020581</ArticleId><ArticleId IdType="pubmed">35417631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>